Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris.
We examined the effects of cilostazol on impaired coronary arterial responses in patients with vasospastic angina (VSA). Thirty patients who were diagnosed with VSA based on an acetylcholine provocation test and 10 subjects with normal coronary arteries were enrolled. The patients were divided into the following 3 groups: no antiplatelet agent treatment group, aspirin treatment, or cilostazol treatment groups. Coronary flow reserve (CFR), coronary flow volume at maximum hyperemia, and epicardial coronary artery diameter after administration of N(G)-monomethyl-L-arginine (L-NMMA) were examined using a Doppler flow wire before and 6 months after the start of this study. CFR, coronary flow volume at maximum hyperemia, and diameter changes by L-NMMA were significantly increased in the cilostazol treatment group compared with the other 2 groups. In conclusion, cilostazol increased CFR and flow-dependent coronary dilation; these changes were attributable to nitric oxide. Cilostazol may improve coronary vascular endothelial dysfunction and coronary hemodynamics in patients with VSA.
Watanabe
Kouki
K
Department of Cardiology, Uwajima City Hospital, Uwajima, Japan. kawatana@uwajima-mh.go.jp
Ikeda
Shuntaro
S
Komatsu
Jirou
J
Inaba
Shinji
S
Suzuki
Jun
J
Sueda
Shozo
S
Funada
Jun-ichi
J
Kitakaze
Masafumi
M
Sekiya
Michihito
M
D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D000077407:Cilostazol; D003326:Coronary Circulation / Q000187:drug effects; D004730:Endothelium, Vascular / Q000187:drug effects*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000627:therapeutic use; D011446:Prospective Studies; D013777:Tetrazoles / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
D013777:Tetrazoles; D014665:Vasodilator Agents; D009569:Nitric Oxide; D000077407:Cilostazol